PRINCETON, NJ – Jan. 29, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it has promoted Amin Rostami, Pharm.D., Ph.D. to senior vice president (SVP) of R&D and chief scientific officer (CSO) at Certara. Professor Rostami previously served as co-founder and vice president of R&D for Certara's Simcyp Business Unit.
"Amin represents the epitome of scientific leadership. He is an original thinker, who can envision how to combine disciplines to disrupt the status quo and improve the drug development paradigm," said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. "He is also tirelessly committed to furthering the science of biosimulation, incredibly patient with his students, and always open to new ideas."
As SVP of R&D and CSO, Professor Rostami will lead Certara's considerable scientific brain trust, which includes almost 100 staff members with Ph.D.s or M.D.s, ensuring that the latest science is incorporated into all of the company's products and activities. He will also partner with Certara's president of technology, and the heads of its business units and corporate sales and marketing teams, to maximize the company's scientific assets.
In addition to his work with Certara, Professor Rostami serves as a professor of systems pharmacology at the University of Manchester, England. In this capacity, he acts as an interface between academia and industry helping to show modelling and simulation applications and demonstrating how they can create the biological data required as input into modeling tools that will positively impact the drug development process, and ultimately patient care.
Professor Rostami has more than 25 years' experience in drug research and 15 years' experience in leadership positions. He has authored or co-authored more than 160 peer-reviewed highly-cited scientific articles (>6,500 journal citations as of January 2015).
A recognized expert in clinical pharmacology, he has been invited to speak at more than 140 international meetings, and is routinely asked by regulatory agencies, including the FDA and EMA, to support and advise on the development of industry guidance on biosimulation.
His achievements have been recognized with both business and scientific awards, including the 2010 Queen's Award for Enterprise, and the OSCAR award (Outstanding Scientific Contribution to Animal Replacement) from the Dr. Hadwen Trust, a UK non-animal medical research charity.
Certara is the global biosimulation technology-enabled drug development and drug safety consulting company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara's solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.